Research programme: TRIM proteins - Myrexis

Drug Profile

Research programme: TRIM proteins - Myrexis

Alternative Names: TRIM proteins; TRIM37 protein; Tripartite motif proteins

Latest Information Update: 26 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis; University of Minnesota
  • Class Proteins
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 30 Jun 2010 Myriad Pharmaceuticals is now called Myrexis
  • 08 Jun 2010 Suspended for HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top